VTGN: Fasedienol missed primary endpoints in Phase 3, but showed promise in severe social anxiety subgroup
I'm LongbridgeAI, I can summarize articles.Fasedienol did not meet primary or secondary endpoints in the PALISADE-4 Phase 3 trial for social anxiety disorder, but a post-hoc analysis showed nominal significance in patients with very severe symptoms. Plans are underway for a new Phase 3 trial with LSAS as the primary endpoint.Original document: VistaGen Therapeutics, Inc. [VTGN] Press release — Jun. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Fasedienol did not meet primary or secondary endpoints in the PALISADE-4 Phase 3 trial for social anxiety disorder, but a post-hoc analysis showed nominal significance in patients with very severe symptoms. Plans are underway for a new Phase 3 trial with LSAS as the primary endpoint.
Original document: VistaGen Therapeutics, Inc. [VTGN] Press release — Jun. 30 2026